These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 2196627

  • 1. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine.
    DeVeaugh-Geiss J, Katz R, Landau P, Goodman W, Rasmussen S.
    Psychopharmacol Bull; 1990; 26(1):54-9. PubMed ID: 2196627
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ.
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A predictive study of obsessive-compulsive disorder response to clomipramine.
    Alarcon RD, Libb JW, Spitler D.
    J Clin Psychopharmacol; 1993 Jun; 13(3):210-3. PubMed ID: 8354737
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
    Pato MT, Hill JL, Murphy DL.
    Psychopharmacol Bull; 1990 Jun; 26(2):211-4. PubMed ID: 2236458
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical features associated with treatment response in obsessive-compulsive disorder.
    Shavitt RG, Belotto C, Curi M, Hounie AG, Rosário-Campos MC, Diniz JB, Ferrão YA, Pato MT, Miguel EC.
    Compr Psychiatry; 2006 Jun; 47(4):276-81. PubMed ID: 16769302
    [Abstract] [Full Text] [Related]

  • 14. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
    Hantouche EG, Bouhassira M, Lancrenon S.
    Encephale; 2000 Jun; 26(6):73-83. PubMed ID: 11217541
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Hungarian translation of the Dimensional Yale-Brown Obsessive-Compulsive Scale and our first experiences with the test].
    Harsányi A, Csigó K, Demeter G, Rajnai C, Németh A, Racsmány M.
    Psychiatr Hung; 2009 Jun; 24(1):18-59. PubMed ID: 19542567
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Efficacy assessment of fluoxetine treatment of outpatients with obsessive-compulsive disorder: a preliminary report].
    Wandzel L.
    Psychiatr Pol; 1997 Jun; 31(4):429-35. PubMed ID: 9527686
    [Abstract] [Full Text] [Related]

  • 20. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
    Rabinowitz I, Baruch Y, Barak Y.
    Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.